my community channel

Biogen Idec announced that enrollment is complete in the ASSURANCE trial, a long-term follow-up study which will assess up to 15 years of Avonex(R) (interferon beta-1a) treatment in an effort to provide detailed data on the long term efficacy of the drug.

ASSURANCE is a multi-center, open-label follow-up study of patients with relapsing remitting multiple sclerosis (MS) treated with Avonex or placebo for at least two years in the phase III pivotal trial. In the trial, 136 of a possible 172 patients were identified for this study at four major MS centers including: Cleveland Clinic Foundation, The State University of New York at Buffalo, Oregon Health and Science University and Georgetown University Medical Center.

The 15-year follow-up study is designed to determine the effect of long term Avonex treatment on disability progression and quality of life. Additionally, the study will assess the impact of treatment on patients' independent living ability. Outcomes of this study will potentially provide further evidence of the benefits of initial and continued treatment with Avonex..............

For the complete report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing Research : AVONEX® and REBIF®